Deborah Waterhouse: Thanks, Andrew. So in terms of barriers to switch in the long-acting market actually they’re pretty typical to the barriers that you see across many long-acting injectables that are in the Medicare Part B and part is about clinic capacity. So for us that is a barrier, but we’re seeing the belief in physicians increase that long-acting is going to be favorably a bigger part of the way that they treat their HIV patient population. So we are seeing them expanding capacity to be it’s a slow journey. The second thing is the ability to get physicians offices ready and able to manage their way through the benefit verification the element of specialty pharmacy versus buy and bill. Again, we are seeing more and more uptake and more and more process flows within the clinician offices that are making this faster and slicker, but still is a learning journey as we are building a brand-new market for HIV physicians.
So I would say complexity around payer and pharmacy strengthened buying bill and the capacity to inject in the two biggest barriers and we’re seeing significant progress on all of those areas which is why we’re seeing the continued significant growth amongst long-acting injectables in both preps and in treatment mainly, because there is enormous patient demand and that just keeps on growing as awareness grows. In terms of Exivir, I’m not going to comment on any of the litigation but we have our own in-house long-acting injectable that were formulating cabotegravir to get to every four and hopefully we’ll be able to get to where we can get to every six months either with VH184 or other options. And we’ve also got in-house options that can take us to every 12 months, but we keep an eye on the whole landscape from a BD perspective of HIV.
And if there is something to do a deal or we will actually do that.
Emma Walmsley: Next question, please.
Nick Stone: Okay. Our next question is from Graham Parry at Bank of America. Over to you, Graham.
Emma Walmsley: Hi, Graham.
Graham Parry: Thanks for taking the questions. It’s — going back to Arexvy in the third season data can you just confirm that there’s no vaccine efficacy measurement to compare one and done vaccination with and every other year vaccination in either the RSV 006 or 004 trials? And if it is just immunogenicity data that you’re going to be using there. How do you go to convince them that a boost in immunogenicity in the third season would correlate with vaccine efficacy when we didn’t see that in the first season in data? And then second question just any sense of what vantage of the high-risk or comorbid population so let’s say over 80s or the comorbid population has been vaccinating with the Arexvy between now? Or has it been across a fairly broad range? Thank you.
Emma Walmsley: So very briefly Luke any comment on the penetration and then – for Tony.
Luke Miels: Yeah. It’s about 13% is the older individuals so 65-plus. It’s about 4% in the 60 to 64. That’s the only data we have at this point Graham but we will get more in Q2.
Tony Wood: And on the third season the comparison will be exactly the same as the one we took in second season Graham. So that is vaccine efficacy based on a three-year duration versus a three-year. Sorry two-year.
Nick Stone: Okay. So I’m going to try and push us a little bit over mindful of the core starting but can we take the next question from Mark Purcell at Morgan Stanley.
Mark Purcell: Yeah. Thanks very much, Nick. Just a quick one sticking on HIV. Ahead of the CROI data historically Phase II data has translated very nicely into Phase III profile. So when it comes to assessing your combination options and the 4-month formulations how confidently should we be extrapolating Phase II data into Phase III and effectively the derisking of the portfolio strategy?
Deborah Waterhouse: So just to answer that very quickly. So we’re incredibly confident in our ability to replace a significant proportion of the revenue that will be lost through the dolutegravir patents expiry. This is a big year for us. So we’ll be presenting data at CROI we’ll be starting the Phase III study for that every four month prep. We’ll be regimen selecting every four month for treatments and we’ll also be regimens selecting for our survival [ph]. So I would say we’re extremely confident in the progression of our HIV pipeline. I’m very confident in the statement that we’ve been measuring for some time that we will be able to potentially replace a significant proportion of the revenue that you’ll lose when dolutegravir dose.
Nick Stone: We’ve got two more questions. I’m going to take the next question from Kerry Holford of Berenberg. Kerry, over to you.
Kerry Holford: Hi. Thanks Nick. Just one final pipeline question. Well, recently launched product question Ojjaara. I know, it’s early days about how is the US launch progressing relative to expectations, and in which line of therapy patients predominantly using this drug? Thank you.
Emma Walmsley: Very well. Luke?
Luke Miels: I’ll go quickly. So, 750 patients since launch, 43% of them are in academic centers, 57% are in community centers. Market research is very, very encouraging. Unaided awareness is well above benchmarks, aided awareness is 99%. I’m not sure that 1%. We’ve got around 15% patient share in patients with anemia and about 25% share in the second line. If you look at the intent to prescribe one-quarter of doctors have already prescribed it, and over 64% who have not prescribed intent to prescribe over the next few months. So, very encouraging, very exciting launch.
Emma Walmsley: Great. And so last question, Nick.
Nick Stone: Last question. So, Steve Scala, TD Cowen. Over to you, Steve.
